ELITE PHARMACEUTICALS INC /NV/
Close on Oct 19, 2026
- Market cap
- $283.02M
- P/E (TTM)
- 5.0
- Dividend yield
- –
Earnings
Next report expected Nov 13, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2027 Ended Jun 30, 2026 | Aug 13, 2026 | During market hours | $32.40M | – | – |
| Q4 FY2026 Ended Mar 31, 2026 | Jun 29, 2026 | During market hours | $148.90M | – | – |
| Q3 FY2026 Ended Dec 31, 2025 | Feb 17, 2026 | During market hours | $31.60M | – | – |
| Q2 FY2026 Ended Sep 30, 2025 | Nov 14, 2025 | During market hours | $36.30M | – | – |
| Q1 FY2026 Ended Jun 30, 2025 | Aug 14, 2025 | During market hours | $40.20M | – | – |
| Q4 FY2025 Ended Mar 31, 2025 | Jun 30, 2025 | During market hours | – | – | – |
| Q3 FY2025 Ended Dec 31, 2024 | Feb 13, 2025 | During market hours | $14.40M | – | – |
| Q2 FY2025 Ended Sep 30, 2024 | Nov 14, 2024 | During market hours | $18.90M | – | – |
| Q1 FY2025 Ended Jun 30, 2024 | Jul 1, 2024 | During market hours | – | – | – |
| Q3 FY2024 Ended Dec 31, 2023 | Feb 14, 2024 | During market hours | – | – | – |
| Q2 FY2024 Ended Sep 30, 2023 | Nov 14, 2023 | During market hours | – | – | – |
Press releases
Announcements Elite Pharmaceuticals filed with the SEC
Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 ended June 30, 2026
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update
Regulation FD disclosure · EX-99.1 to Form 8-K/A
Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Announces Commercial Launch of Generic Requip XL ®
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2026
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update
Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Positive Results from a Pivotal Bioequivalence Study
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Announces Filing of Abbreviated New Drug Application with the U.S. Food and Drug Administration for Generic Anticoagulant
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update
Regulation FD disclosure · EX-99.1 to Form 8-K/A
Elite Pharmaceuticals Receives FDA Approval for
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2026 ended June 30, 2025 and Provides Conference
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2025
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Elite Pharmaceuticals, Inc. to Host Conference
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Announces Commercial Launch of Oxycodone and Acetaminophen Tablets
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals, Inc. Announces First Shipment of Product from New Facility and Packaging Line
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Announces Commercial Launch of Generic Vyvanse®
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Announces Commercial Launch of Acetaminophen and Hydrocodone Tablets
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Receives FDA Approval for Generic Vyvanse®
Regulation FD disclosure · EX-99.1 to Form 8-K
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals’ Generic Adderall ® Receives Marketing Approval from the Israeli Ministry of Health
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Announces Commercial Launch of Acetaminophen and Codeine Phosphate Tablets
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Announces Commercial Launch of Generic Methotrexate Sodium
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2025 ended June 30, 2024 and Provides Conference
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Elite Pharmaceuticals, Inc. Reports Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Elite Pharmaceuticals Receives FDA Approval for Generic Methotrexate
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Files ANDA with US FDA to Market Central Nervous System Stimulant
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Announces First Product Shipment of Generic Adderall XR®
Other events · EX-99.1 to Form 8-K
Pharmaceuticals, Inc. Reports Financial Results for Second Quarter of Fiscal Year 2024 ended September 30, 2023
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Files ANDA with US FDA to Market Opiate Analgesic Product
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals, Inc. Reports Financial Results for First Quarter of Fiscal Year 2024
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2023
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K